Evolus Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Good afternoon. I am Louise Chen, the large-cap and biopharma analyst here at Cantor. Thank you for joining us today for our virtual fireside chat with Evolus.
We are excited to have with us today David Moatazedi, President and CEO; Lauren Silvernail, Chief Financial Officer; and David Erickson in Investor Relations to discuss the uptake of Jeuveau and also the EU launch in early 2022.
Despite COVID-19, the uptake of Jeuveau and its underlying growth has been very strong, and we continue to expect Jeuveau to be at least the #2 toxin on the market, and for Evolus to expand it's aesthetic offerings to build out a leading aesthetic company over time.
Questions & Answers
So with that, I wanted to ask you the first question I have for you all. For investors who may be new to the toxin story, can you give us a sense of the size of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
